Monty Morris
Medical · Justin, TXNPI 1962404822
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.8% of the total across 138 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by AbbVie at 37.8% of the total.
Across 138 payments — averaging $16.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$872
- Paratek Pharmaceuticals, Inc.$176
- Axsome Therapeutics, Inc.$155
- Antares Pharma, Inc.$121
- Lilly USA, LLC$104
- Currax Pharmaceuticals LLC$104
- plus $777 from 19 others
What the payments were for
- Food & beverage$2,25998%
- Education$502%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 58 | $872 |
| Paratek Pharmaceuticals, Inc. | 9 | $176 |
| Axsome Therapeutics, Inc. | 7 | $155 |
| Antares Pharma, Inc. | 7 | $121 |
| Lilly USA, LLC | 6 | $104 |
| Currax Pharmaceuticals LLC | 6 | $104 |
| Pfizer | 5 | $94 |
| Idorsia Pharmaceuticals US Inc | 5 | $85 |
| Clarus Therapeutics Inc. | 5 | $85 |
| Verity Pharmaceuticals Inc. | 4 | $78 |
| Novo Nordisk | 5 | $75 |
| Amgen(2 entities) | 4 | $61 |
| Acella Pharmaceuticals, LLC | 3 | $60 |
| IBSA Pharma Inc. | 2 | $38 |
| Tolmar, Inc. | 2 | $27 |
| Shield Therapeutics Inc | 1 | $25 |
| Virtus Pharmaceuticals LLC | 1 | $21 |
| Biohaven Pharmaceuticals, Inc. | 1 | $20 |
| Halozyme Inc | 1 | $19 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Boehringer Ingelheim | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| AstraZeneca | 1 | $14 |
| Jazz Pharmaceuticals Inc. | 1 | $13 |
How this compares
$2,309 in reported general payments places this provider in the 70th percentile of 1,490 medical providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Testosterone Cypionate | 26 | $1,568 |
| Liothyronine Sodium | 12 | $578 |
| Levothyroxine Sodium | 32 | $252 |
| Zolpidem Tartrate | 15 | $144 |
| Anastrozole | 12 | $141 |
| Alprazolam | 48 | $93 |
| Losartan Potassium | 16 | $77 |
| Lisinopril | 15 | $76 |
| Hydrochlorothiazide | 11 | $53 |
| Promethazine Hcl | 12 | $18 |
Paid to pharmacies, not to this prescriber.
Other medical in Justin
- Mark DavisFort Worth$1M
- Joey Dixon-JulianBoerne$458K
- Terry FaleyeKingwood$243K
- Kimberly PoarchDallas$166K
- Erin DuhaimeDallas$150K
- Shakira CabreraSan Antonio$116K
- Danny DeckardDallas$101K
- Courtney AldridgeSan Antonio$89K
- Janine ShinnDallas$84K
- Radha BernanderKaty$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.